Table 1.

Vaccination and testing schedule for primary and annual FIV vaccination studies. FIV antibody testing included testing with a variety of point-of-care (PoC) antibody kits, an anti-p24 antibody microsphere immunoassay (MIA), and an anti-gp40 antibody ELISA. PCR testing was performed by a commercial veterinary laboratory (FIV RealPCR^TM, IDEXX Laboratories). For MIA and ELISA testing, samples from two weeks after the third primary FIV dose were compared to samples from two weeks after annual FIV vaccination (i.e., day 70 * vs. day 14 *), and samples from four weeks after the third primary FIV dose were compared to samples from four weeks after annual FIV vaccination (i.e., day 84 ^† vs. day 28 ^†). Superscripts denote equivalent time points tested for primary vs. annual vaccination. Additional MIA and ELISA testing at other time points was performed (brackets) but not used for comparisons between vaccination groups; these results are included as Supplementary data.

	Day 0	Day 14	Day 28	Day 42	Day 56	Day 70 *	Day 84 †	Day 238
Primary vaccination study (n = 11)
FIV vaccination	×		×		×
PoC antibody testing	×	×	×	×	×	×	×	×
MIA p24/ELISA gp40 testing	×	(×)	(×)	(×)	(×)	×	×	(×)
PCR testing	×							×
	Day 0	Day 14 *	Day 28 †	Day 42
Annual vaccination study (n = 10)
FIV vaccination	×
PoC antibody testing	×	×	×	×
MIA p24/ELISA gp40 testing	×	×	×	(×)
PCR testing	×			×